| COMIRNATY (mRNA encoding SARS-CoV-2 spike protein, 5’ [m27,3’-OGppp(m12’-O)ApG] cap, 110-nucleotide 3' poly(A) tail with a 10-nucleotide linker sequence) |
BioNTech Manufacturing GmbH |
Vaccine |
Authorized |
|
No |
127 |
| NUVAXOVID (SARS-CoV-2 recombinant spike protein) |
Novavax Inc |
Vaccine |
Authorized |
|
No |
126 |
| SPIKEVAX (mRNA encoding SARS-CoV-2 spike protein, 5’(m7G-5’-ppp-5’-Gm) cap, 100-nucleotide 3' poly(A) tail) |
Moderna Biopharma Canada Corporation |
Vaccine |
Authorized |
|
No |
125 |
| Nuvaxovid XBB.1.5 (SARS-CoV-2 recombinant spike protein) Replaced with NUVAXOVID (SARS-CoV-2 recombinant spike protein) [JN.1 strain] on September 19, 2024 |
Novavax Inc |
Vaccine |
Authorized |
|
No |
124 |
| COMIRNATY Omicron XBB.1.5 (raxtozinameran) Replaced with COMIRNATY (mRNA encoding SARS-CoV-2 spike protein, 5’ [m27,3’- OGppp(m12’-O)ApG] cap, 110-nucleotide 3' poly(A) tail with a 10-nucleotide linker sequence) [KP.2 strain] on September 24, 2024 |
BioNTech Manufacturing GmbH |
Vaccine |
Authorized |
|
No |
123 |
| SPIKEVAX XBB.1.5 (andusomeran) Replaced with SPIKEVAX (mRNA encoding SARS-CoV-2 spike protein, 5’(m7G-5’- ppp-5’-Gm) cap, 100-nucleotide 3' poly(A) tail) [KP.2 strain] on September 17, 2024 |
Moderna Biopharma Canada Corporation |
Vaccine |
Authorized |
|
No |
122 |
| SPIKEVAX Bivalent Original / Omicron BA.4/5 (elasomeran/ davesomeran) Cancelled by sponsor January 19th, 2024 |
Moderna Biopharma Canada Corporation |
Vaccine |
Authorized |
|
No |
117 |
| COMIRNATY ORIGINAL/OMICRON BA.1 (tozinameran and riltozinameran) Cancelled by sponsor May 3rd, 2024 |
BioNTech Manufacturing GmbH |
Vaccine |
Authorized |
|
No |
116 |
| ACTEMRA (tocilizumab) |
Hoffmann-La Roche Limited |
Treatment |
Authorized |
|
No |
115 |
| COMIRNATY Original & Omicron BA.4/BA.5 (tozinameran / famtozinameran) Cancelled by sponsor May 3rd, 2024 |
BioNTech Manufacturing GmbH |
Vaccine |
Authorized |
|
No |
114 |
| SPIKEVAX Bivalent (elasomeran/ imelasomeran) Cancelled by sponsor January 19th, 2024 |
Moderna Biopharma Canada Corporation |
Vaccine |
Authorized |
|
No |
111 |
| EVUSHELD (cilgavimab / tixagevimab) Cancelled by sponsor Marc 27th, 2024 |
AstraZeneca Canada Inc. |
Treatment |
Authorized |
|
No |
109 |
| Covifenz (virus-like particles (VLP) of SARS-CoV-2 spike protein) Cancelled by sponsor March 31st, 2023 |
Medicago Inc |
Vaccine |
Authorized |
|
No |
106 |
| NUVAXOVID (SARS-CoV-2 recombinant spike protein) Cancelled by sponsor February 29th, 2024 |
Novavax Inc |
Vaccine |
Authorized |
|
No |
104 |
| PAXLOVID (nirmatrelvir / ritonavir) |
Pfizer Canada ULC |
Treatment |
Authorized |
|
No |
102 |
| Sotrovimab (sotrovimab) Cancelled by sponsor April 29th, 2024 |
GlaxoSmithKline Inc |
Treatment |
Authorized By Interim Order |
|
No |
36 |
| Casirivimab and imdevimab (casirivimab / imdevimab) Cancelled by sponsor June 21st, 2024 |
Hoffmann-La Roche Limited |
Treatment |
Authorized By Interim Order |
|
No |
34 |
| JCOVDEN (Ad26.COV2.S [recombinant]) Cancelled by sponsor July 30th, 2023. Previously Janssen COVID-19 Vaccine. |
Janssen Inc |
Vaccine |
Authorized By Interim Order |
|
No |
27 |
| COVISHIELD (ChAdOx1-S [recombinant]) Expired September 16 2021 |
Verity Pharmaceuticals Inc/Serum Institute of India (in partnership with AstraZeneca Canada Inc) |
Vaccine |
Authorized By Interim Order |
|
No |
29 |
| Vaxzevria (ChAdOx1-S [recombinant]) Cancelled by sponsor December 19th, 2023. Previously Astrazeneca Covid-19 Vaccine. |
AstraZeneca Canada Inc. |
Vaccine |
Authorized By Interim Order |
|
No |
28 |
| SPIKEVAX (elasomeran) Cancelled by sponsor January 19th, 2024. Previously COVID-19 Vaccine Moderna. |
Moderna Biopharma Canada Corporation |
Vaccine |
Authorized |
|
No |
15 |
| Comirnaty (tozinameran) Cancelled by sponsor May 3rd, 2024. Previously Pfizer-BioNTech COVID-19 Vaccine. |
BioNTech Manufacturing GmbH |
Vaccine |
Authorized By Interim Order |
|
No |
16 |
| Bamlanivimab (bamlanivimab) Cancelled by sponsor February 13th, 2024 |
Eli Lilly Canada Inc |
Treatment |
Authorized By Interim Order |
|
No |
8 |
| Veklury (remdesivir) |
Gilead Sciences Canada Inc |
Treatment |
Authorized |
|
No |
9 |
| Nitric oxide (nitric oxide) |
Sanotize Research & Development Corp. |
Treatment |
Under review |
Under review |
Yes |
76 |
| COVID-19 Vaccine Moderna – Application for Pediatric Use (ages 12-17) (mRNA-1273 SARS-CoV-2) |
ModernaTX, Inc. |
Vaccine |
Under review |
Under review |
No |
55 |
| Regdanvimab (regdanvimab) |
Celltrion HealthCare Co Ltd |
Treatment |
Under review |
Under review |
No |
53 |
| Olumiant (baricitinib) |
Eli Lilly Canada Inc |
Treatment |
Under review |
Under review |
Yes |
39 |
| Coronavirus-like Particle (CoVLP) COVID-19 Vaccine (coronavirus-like particle [CoVLP]) |
Medicago Inc |
Vaccine |
Under review |
Under review |
No |
38 |
| Leronlimab (leronlimab) |
CytoDyn, Inc. |
Treatment |
Under review |
Under review |
No |
35 |
| Bamlanivimab and etesevimab (LY-CoV555 / LY-CoV016) |
Eli Lilly Canada Inc |
Treatment |
Under review |
Under review |
No |
32 |
| Novavax COVID-19 Vaccine (NVX-CoV2373) |
Novavax Inc |
Vaccine |
Under review |
Under review |
No |
31 |
| Favipiravir (favipiravir) |
Dr Reddys Laboratories Ltd |
Treatment |
Under review |
Under review |
|
17 |
